The immune response to tumors

Current Protocols in Immunology

Volumn , Issue SUPPL. 85, 2009, Pages

  Dougan, Michael ^a   Dranoff, Glenn ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antitumor immunity; Cancer; Immunoediting; Immunosuppression; Immunotherapy; Inflammation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTINEOPLASTIC AGENT; APRIL PROTEIN; ARGINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE SYNTHASE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CYTOKINE RELEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; NEOPLASM; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; IMMUNOLOGIC SURVEILLANCE; INFLAMMATION; NEOPLASMS; ONCOGENE PROTEINS; TUMOR ESCAPE;

HARNESS;

EID: 64249095156     PISSN: 19343671     EISSN: 1934368X     Source Type: Journal    
DOI: 10.1002/0471142735.im2011s85     Document Type: Review

References (16)

1. Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H., and Freeman, G.J. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27:111-122.
2. Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., Cross, R., Sehy, D., Blumberg, R.S., andVignali, D.A. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566-569.
3. Curiel, T.J. 2007. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117:1167-1174.
4. Dougan,M. and Dranoff, G. 2008. Immune therapy for cancer. Annu. Rev. Immunol. 2008 Nov 13. Epub ahead of print.
5. Dunn, G.P., Old, L.J., and Schreiber, R.D. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.
6. El-Omar, E.M., Carrington, M., Chow, W.H., McColl, K.E., Bream, J.H., Young, H.A., Herrara, J., Lissowska, J., Yuan, C.C., Rothman, N., Lanyon, G., Margin, M., Fraumeni, J.F., Jr., and Rabkin, C.S. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398-402.
7. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoue, F., Bruneval, P., Cugnenc, P.H., Trajanoski, Z., Fridman, W.H., and Pages, F. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964.
8. Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Dagnoff, M.F., and Karin, M. 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitisassociated cancer. Cell 118:285-296.
9. Karin,M. and Greten, F.R. 2005. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5:749-759.
10. Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., and Schreiber, R.D. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903-907.
11. Lin, W.W. and Karin, M. 2007. A cytokinemediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117:1175-1183.
12. Munn, D.H. and Mellor, A.L. 2007. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117:1147-1154.
13. Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A.M., and Karin,M. 2007. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121-124.
14. Rakoff-Nahoum, S. andMedzhitov, R. 2007. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317:124-127.
15. Sica, A. and Bronte, V. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117:1155-1166.
16. Swann, J.B. and Smyth, M.J. 2007. Immune surveillance of tumors. J. Clin. Invest. 117:1137-1146.